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1  | INTRODUC TION
Bacterial persisters are cells that transiently display antibiotic 
tolerance due to a dormant physiology and constitute a subpop-
ulation of cells within the overall bacterial population (Balaban 
et al., 2019). This phenomenon has been linked to treatment failure 
of chronic and relapsing infections in different clinical settings 
(Fauvart, De Groote, & Michiels, 2011; Harms, Maisonneuve, & 
Gerdes, 2016; Lewis, 2010). One common example is urinary tract 
infections (UTIs) that often relapse and are frequently caused by 
uropathogenic strains of Escherichia coli (UPEC) (Flores-Mireles, 
Walker, Caparon, & Hultgren, 2015). These bacteria are thought 
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Abstract
Antibiotic-tolerant	persisters	are	often	implicated	in	treatment	failure	of	chronic	and	
relapsing bacterial infections, but the underlying molecular mechanisms have re-
mained elusive. Controversies revolve around the relative contribution of specific ge-
netic	switches	called	toxin–antitoxin	(TA)	modules	and	global	modulation	of	cellular	
core functions such as slow growth. Previous studies on uropathogenic Escherichia 
coli observed impaired persister formation for mutants lacking the pasTI locus that 
had	been	proposed	to	encode	a	TA	module.	Here,	we	show	that	pasTI	is	not	a	TA	mod-
ule and that the supposed toxin PasT is instead the bacterial homolog of mitochon-
drial protein Coq10 that enables the functionality of the respiratory electron carrier 
ubiquinone as a “lipid chaperone.” Consistently, pasTI mutants show pleiotropic phe-
notypes linked to defective electron transport such as decreased membrane poten-
tial and increased sensitivity to oxidative stress. We link impaired persister formation 
of pasTI mutants to a global distortion of cellular stress responses due to defective 
respiration. Remarkably, the ectopic expression of human coq10 largely complements 
the respiratory defects and decreased persister levels of pasTI mutants. Our work 
suggests that PasT/Coq10 has a central role in respiratory electron transport that is 
conserved from bacteria to humans and sustains bacterial tolerance to antibiotics.
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to persist during antibiotic treatment in rectal reservoirs and in-
tracellular biofilms, and the survival of UPECs isolated from recur-
rent UTIs was shown to correlate with higher levels of persister 
cells	detectable	 in	the	population	(Anderson	et	al.,	2003;	Blango	
&	Mulvey,	 2010;	 Glover,	Moreira,	 Sperandio,	 &	 Zimmern,	 2014;	
Goneau et al., 2014).
Although	 persister	 cells	 are	 ubiquitous	 and	 their	 formation	
and evolution have been studied in multiple human pathogens 
(Michiels, Van den Bergh, Verstraeten, Fauvart, & Michiels, 2016), 
the molecular mechanisms underlying their antibiotic tolerance 
have remained largely elusive. Mechanistic studies have been 
performed primarily in laboratory model strains like E. coli K-12 
where multiple different pathways of persister cell formation have 
been	described	 (Harms	et	 al.,	 2016;	 Lewis,	 2010).	Among	 these,	
the dormant physiology of persister cells has been linked repeat-
edly	 to	 the	 reversible	 activation	 of	 toxin–antitoxin	 (TA)	 systems	
in different strains of E. coli as well as closely related Salmonella 
Typhimurium	 (Dörr,	 Vulic,	 &	 Lewis,	 2010;	 Harms	 et	 al.,	 2016;	
Helaine	 et	 al.,	 2014;	 Norton	 &	 Mulvey,	 2012;	 Verstraeten	
et	 al.,	 2015).	 TA	 systems	 are	 composed	 of	 a	 toxin	 protein	 that	
can inhibit key cellular processes and a cognate antitoxin that re-
presses the toxin's activity until it is degraded in response to cel-
lular	signaling	(Harms,	Brodersen,	Mitarai,	&	Gerdes,	2018).	They	
can therefore act as genetically controlled switches to reversibly 
shut down bacterial growth, and as such, it is generally intuitive 
that	TA	systems	might	be	well	suited	to	control	persister	cell	for-
mation, survival, and resuscitation (Ronneau & Helaine, 2019). 
However,	 the	 relative	 importance	 of	 specific	 factors	 such	 as	 TA	
systems has remained controversial compared to global changes 
via modulation of the cellular core machinery including electron 
transport	 or	 ATP	 synthesis	 (Goneau	 et	 al.,	 2014;	 Goormaghtigh	
et	al.,	2018;	Harms	et	al.,	2016;	Pontes	&	Groisman,	2019;	Shan	
et al., 2017). We previously discovered that a once well-estab-
lished	 link	between	ten	particular	TA	systems	of	E. coli K-12 and 
persister	 formation	 is	wrong	 (Goormaghtigh	et	al.,	2018;	Harms,	
Fino, Sørensen, Semsey, & Gerdes, 2017), and the link between 
TA	systems	and	persister	formation	in	Salmonella Typhimurium has 
also recently been disputed (Pontes & Groisman, 2019).
Given these debates, we became interested in a study that found 
the pasTI	TA	module	of	UPEC	strain	CFT073	to	be	critical	for	anti-
biotic-tolerant	persister	cells	(Norton	&	Mulvey,	2012).	Remarkably,	
the orthologous system in E. coli K-12, ratAB, seemed to play no role 
in persister formation under the same conditions. However, the mo-
lecular basis of PasTI-dependent drug tolerance in UPECs remained 
unclear.	Previous	work	had	proposed	that	the	RatA	toxin	of	E. coli 
K-12 is a translation inhibitor that interferes with 70S ribosome as-
sembly but did not experimentally confirm the role of RatB as the 
cognate	antitoxin,	questioning	the	notion	that	RatAB/PasTI	is	indeed	
a	TA	system	(Zhang	&	Inouye,	2011).
In this study, we therefore aimed at uncovering the molecular 
activity	and	biological	 function	of	PasTI/RatAB	 in	E. coli to shed 
more	light	on	the	role	of	this	TA	system	in	persister	formation	and	
persister cells in clinical contexts. While we readily reproduced 
that PasT is critical for the formation or survival of ciprofloxa-
cin-tolerant cells by E. coli CFT073 and other pathogenic entero-
bacteria,	we	could	not	confirm	that	PasTI	is	a	TA	system.	Instead,	
we show that PasT is the bacterial homolog of mitochondrial 
protein Coq10 that acts as an important accessory factor in the 
ubiquinone-dependent electron transport chain (ETC). We find 
that E. coli mutants lacking pasT display the same pleiotropic phe-
notypes as yeast coq10 mutants including decreased membrane 
potential, increased sensitivity to oxidative stress, and modestly 
decreased ubiquinone biosynthesis. Remarkably, these signs of 
defective respiration in E. coli can be complemented by ectopic 
expression of human coq10, suggesting that PasT and Coq10 are 
functionally equivalent. We therefore conclude that PasT is a 
previously unrecognized player in bacterial respiratory electron 
transport and likely affects antibiotic tolerance indirectly via its 
roles in redox balance and/or energy metabolism.
2  | MATERIAL S AND METHODS
2.1 | Bacterial handling and culturing
Escherichia coli was routinely cultured in LB or M9 liquid medium 
at 37°C in glass culture tubes or Erlenmeyer flasks with agitation 
at 160 rpm, usually in a water bath shaker for physiological ex-
periments. LB agar plates were routinely used as a solid medium. 
Selection for plasmid maintenance was performed with ampicil-
lin at 30 µg/ml (mini-R1 origin of replication) or 100 µg/ml (other 
origins of replication), chloramphenicol at 25 µg/ml, and kanamy-
cin at 25 µg/ml. Plac was induced with 1 mM of isopropyl β-d-
1-thiogalactopyranoside (IPTG), while ParaB was induced with 
0.2% w/v of l-arabinose. Whenever appropriate, liquid and solid 
media were supplemented with 1% w/v d-glucose to reduce basal 
expression of both Plac and ParaB promoters through catabolite 
repression. Unless indicated differently, the complementation of 
bacterial mutants with E. coli genes was performed using low-copy 
plasmids	 (pNDM220	 derivatives)	 carrying	 these	 genes	 including	
their own promoter, so that no ectopic induction of the constructs 
was necessary. When enforced expression was required (e.g., for 
the	experiments	shown	in	Figure	1	and	Figure	A6f	in	Appendix	2)	
or to test heterologous complementation with distant homologs 
(e.g.,	 Figure	 8),	 isogenic	 plasmids	 encoding	 genes	 without	 their	
endogenous promoters were used and the bacteria were continu-
ously cultured in the presence of 1 mM of IPTG in overnight cul-
tures and throughout the experiment to induce expression from 
the Plac	promoter	of	pNDM220	derivatives	(see	all	plasmids	listed	
in	Table	A2	in	Appendix	1).
Bacteria were grown anaerobically on LB agar plates incubated 
in	 a	 plastic	 jar	 (cat#	 1.16387.0001;	 Merck)	 with	 an	 anaerobic	 at-
mosphere	 generation	 bag	 (cat#	 68061;	 Sigma).	 The	 formation	 of	
an	 anaerobic	 atmosphere	 was	 confirmed	 using	 Anaerotest	 strips	
(cat#	1.15112.0001;	Merck).	1%	w/v	d-glucose was added as a fer-
mentable carbon source to LB agar plates incubated anaerobically.
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2.2 | Preparation of culture media
Lysogeny broth (LB) was prepared by dissolving 1% w/v of tryp-
tone	(cat#	LP0042;	Oxoid),	0.5%	w/v	of	yeast	extract	(cat#	LP0021;	
Oxoid),	 and	 1%	 w/v	 of	 sodium	 chloride	 (cat#	 27810.364;	 VWR	
Chemicals) in Milli-Q H2O and sterilized by autoclaving. LB agar 
plates were prepared by supplementing LB medium with agar and 
1.5% w/v before autoclaving. M9 medium was prepared according 
to the Cold Spring Harbor Protocols (M9 minimal medium (standard), 
2010) with modifications in the form of 1× M9 salts (stock solution 
prepared from 5× M9 salts, see below) supplemented with 0.4% w/v 
Amicase	 (cat#	 1002372245;	 Sigma;	 from	 10%	 w/v	 sterile-filtered	
stock), 0.4% w/v d-glucose	 (cat#	 101176K;	 VWR	Chemicals;	 from	
40% w/v autoclaved stock), 2 mM MgSO4	(cat#.	25.165.292;	VWR	
Chemicals),	 1	 µg/ml	 thiamine	 (cat#	 T1270;	 Sigma),	 and	 100	 µM	
CaCl2	(cat#	C3306;	Sigma).	The	5×	M9	salt	solution	was	prepared	by	
dissolving	25.6	g	Na2HPO4	(cat#	S9390;	Merck),	6	g	KH2PO4	(cat#	
P0662;	 Sigma),	 1	 g	NaCl	 (cat#	277810.364;	VWR	Chemicals),	 and	
2	g	NH4Cl	(cat#	5470.1;	Roth)	in	400	ml	Milli-Q	H2O supplemented 
with 20 µl of a 10 mg/ml FeSO4	solution	(cat#	F8048;	Sigma).	After	
confirming a pH of 7.4, the solution was sterile-filtered and stored 
in the dark.
2.3 | Strain construction
E. coli K-12 MG1655 ΔratAB and E. coli CFT073 ΔpasTI mutants 
(with	identifiers	CF083	and	CF069/CF378,	respectively)	were	con-
structed as scarless deletions using two-step recombineering with 
a double-selectable cassette encoding chloramphenicol resistance 
and sacB (sucrose sensitivity) that was amplified from template plas-
mid pKO4 (Lee et al., 2001). Recombineering functions were ex-
pressed from pWRG99 (Blank, Hensel, & Gerlach, 2011). The first 
step of recombineering replaced the target gene with the double-
selectable cassette, and the second step removed the double-se-
lectable	cassette	via	recombineering	with	a	pair	of	annealed	80-mer	
oligonucleotides composed of twice 40 bp homologies flanking the 
desired deletion (Blank et al., 2011). The negative selection was per-
formed	on	LB	agar	plates	supplemented	with	6%	w/v	sucrose	(cat#	
S0389;	Sigma;	from	a	60%	w/v	sterile-filtered	stock	solution).	E. coli 
K-12 MG1655 and E. coli CFT073 derivatives were routinely trans-
formed	with	plasmids	using	TSS	transformation	(Chung,	Niemela,	&	
Miller,	1989)	and	electroporation,	respectively.	Deletions	of	pasTI in 
E. coli	strains	O157:H7	EDL933	and	55989	as	well	as	 in	Salmonella 
enterica subsp. enterica Typhimurium strain SR-11 were constructed 
using	recombineering	functions	expressed	from	pKM208	of	Murphy	
and Campellone (2003). For E. coli EDL933 and S. enterica SR-11, 
scarless deletions via the double-selectable cassette of pWRG100 
were achieved (see above). For E. coli	55989,	the	pasTI locus was first 
replaced with an FRT-flanked gene cassette encoding kanamycin re-
sistance. In the second step, gene cassettes were removed using Flp 
recombinase expressed from pCP20 in a way that only a short FRT 
scar	 remained.	All	 bacterial	 strains	 used	 in	 this	 study	 are	 listed	 in	
Table	A1	(Appendix	1),	all	plasmids	are	listed	in	Table	A2	(Appendix	
1),	and	all	oligonucleotides	are	listed	in	Table	A3	(Appendix	1).
2.4 | Plasmid construction
Plasmids were constructed using standard techniques of restriction-
based molecular cloning. Briefly, a PCR-amplified fragment and the 
vector backbone were each cut with appropriate FastDigest re-
striction	 enzymes	 (Thermo	 Scientific).	 After	 fragment	 purification	
and	 backbone	 dephosphorylation	 (using	 FastAP	 dephosphorylase;	
Thermo Scientific), the two components were ligated together using 
the T4 ligase (Thermo Scientific). Site-directed mutagenesis of plas-
mids was performed by PCR with partially overlapping primers as 
described	by	Liu	and	Naismith	(2008).	Plasmid	construction	was	al-
ways	confirmed	by	DNA	sequencing.	A	list	of	all	plasmids	used	in	this	
study	as	well	as	details	of	their	construction	are	given	in	Table	A2	
(Appendix	 1).	 The	 sequences	 of	 all	 oligonucleotides	 used	 in	 this	
study	are	listed	in	Table	A3	(Appendix	1).
The open reading frames of Caulobacter crescentus cc1736 and 
human coq10A (one of the two human coq10 isoforms) were ob-
tained from GenScript after codon optimization for heterologous 
expression in E. coli. For coq10, we cloned the C-terminal portion 
homologous to pasT/cc1736	 without	 the	N-terminal	mitochondrial	
signal	peptide	sequence	at	its	5′	end	(see	Figure	A4a	in	Appendix	2).
2.5 | Sequence analyses and in silico predictions
For	 the	 protein	 alignment	 shown	 in	 Figure	 A4a	 of	 Appendix	 2,	
amino acid sequences of E. coli CFT073 PasT (UniProt accession 
Q8FEY4),	C. crescentus	CC1736	(UniProt	accession	Q9A7I7),	Coq10	
of Schizosaccharomyces pombe (UniProt accession Q9USM9), and 
Saccharomyces cerevisiae	 (UniProt	 accession	 Q08058),	 as	 well	 as	
human	 Coq10A	 (UniProt	 accession	 Q96MF6),	 were	 aligned	 using	
MAFFT	 (implemented	 in	Geneious	 v10.1.3)	 and	manually	 curated.	
For the synteny analysis of pasTI loci shown in Figure 3, the pres-
ence of prophages at a known integration hotspot next to ssrA (see 
Mao	et	al.	(2009))	was	detected	with	PHASTER	(Arndt	et	al.,	2016)	
while the integration of other specific gene content was analyzed by 
manual sequence comparisons.
Phyre2 (https://www.sbg.bio.ic.ac.uk/phyre2; Kelley, Mezulis, 
Yates,	Wass,	&	Sternberg,	2015)	was	used	for	the	prediction	of	the	
tertiary	structure	of	PasT	(Figure	A4b	in	Appendix	2).	The	prediction	
of	potential	functional	partners	in	Figure	A4c	in	Appendix	2	was	ob-
tained	using	STRING	(https://strin	g-db.org/;	Szklarczyk	et	al.,	2018).
2.6 | Spot assays
For the detection of bacterial growth inhibition upon expression of 
different proteins, 1.5 ml of dense overnight cultures of E. coli har-
boring	 indicated	 plasmids	 was	 adjusted	 to	 have	 the	 same	 optical	
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density at 600 nm (OD600), washed once, and then serially diluted 
in sterile phosphate-buffered saline (PBS). Subsequently, 10 µl of the 
serial dilutions was spotted on LB agar plates containing indicated 
supplements that induce or repress protein expression. Different 
copy numbers of otherwise isogenic plasmid vectors were achieved 
by merely changing the origin of replication on the otherwise iden-
tical	 plasmid	 backbone.	 Based	 on	 pNDM220	 (mini-R1	 origin,	 low-
copy;	Gotfredsen	&	Gerdes,	1998),	we	thus	created	pAH186_SC101	
and	 pAH186_ColE1	 with	 SC101	 (medium-copy)	 and	 ColE1	 (high-
copy) origins, respectively (Jahn, Vorpahl, Hubschmann, Harms, 
& Muller, 2016). We assume that pasT/ratA	cloned	 in	pNDM220	 is	
expressed at physiologically relevant levels due to a low plasmid 
copy number that should drive expression similar to the native chro-
mosomal	 loci.	 A	 recent	 proteomic	 study	 revealed	 that	 RatA(YfjG)	
and	 RatB(YfjF)	 are	 expressed,	 under	 conditions	 identical	 to	 our	
experimental conditions (M9 medium with glucose as sole carbon 
source), to levels of ca. 30 and 50 molecules per cell, respectively 
(Supplementary Table 9 in Schmidt et al. (2015)).
The	Doc	and	HipA	TA	system	toxins	are	kinases	that	inhibit	bac-
terial growth through phosphorylation and concomitant inactivation 
of	 elongation	 factor	 Tu	 (EF-Tu)	 or	 glutamyl	 tRNA	 synthetase,	 re-
spectively	(Castro-Roa	et	al.,	2013;	Germain,	Castro-Roa,	Zenkin,	&	
Gerdes, 2013). To compare the colony size between strains, 1.5 ml of 
dense overnight cultures was washed in 100 µl of phosphate-buff-
ered saline (PBS), serially diluted in PBS, and spotted (10 µl) on LB 
agar plates. When indicated, LB agar plates were supplemented with 
inducers and/or incubated under anaerobic conditions.
2.7 | Determination of minimum inhibitory 
concentration (MIC)
The MIC of antibiotics for different E. coli strains was determined by 
broth dilution assays. In short, serial 1.5-fold dilutions of antibiotics 
in M9 medium with suitable supplements were inoculated with the 
different bacterial strains as indicated, sealed with a breathable film, 
and agitated at 37°C/160 rpm overnight. The MIC was determined 
as the lowest concentration of antibiotic that prevented bacterial 
growth as detected by visual inspection.
2.8 | Antibiotic tolerance assays
The dynamics of antibiotic tolerance throughout the growth phases 
of E. coli were studied by performing antibiotic killing assays with 
bacterial cultures that had grown for different times after inocula-
tion from overnight culture into the fresh medium as described pre-
viously (Harms et al., 2017). In more detail, overnight cultures were 
inoculated from single colonies into 3 ml of M9 medium and grown 
for	 ca.	 16	 hr	 in	 plastic	 culture	 tubes	 (cat#	 62.515.006;	 Sarstedt).	
Subcultures of 10 ml M9 medium in Erlenmeyer flasks were inocu-
lated 1:100 from these overnight cultures and agitated in a water 
bath	 at	 37°C/160	 rpm.	 All	 viable	 colony-forming	 units	 (cfu)	 and	
antibiotic-tolerant cfu (see below) were determined for isogenic cul-
tures that had grown for different times after subculturing (from 0 hr 
to	8	hr)	and	 represented	 the	spectrum	of	bacterial	growth	phases	
from lag phase over exponential growth into stationary phase (see, 
e.g., the curve of colony-forming units (cfu) plotted over time in 
Figure	2a).	Antibiotic	tolerance	was	assayed	by	treating	3	ml	aliquots	
of culture in plastic tubes with lethal concentrations of ciprofloxacin 
(10 µg/ml), ampicillin (100 µg/ml), or colistin (6.6 µg/ml) for 5 hr at 
37°C/160 rpm. In parallel, cfu counts of the same untreated cultures 
were determined by plating serial dilutions on LB agar plates. The 
MIC of ciprofloxacin for E. coli K-12 MG1655 and CFT073 includ-
ing	 all	 tested	mutant	 derivatives	 was	 0.00780	 µg/ml,	 that	 is,	 the	
bacteria were treated with >1,000× MIC to avoid secondary effects 
of prophage activation (Harms et al., 2017). The MIC of colistin for 
E. coli K-12 MG1655 and CFT073 including all tested mutant deriva-
tives was 1.3 µg/ml, that is, the treatment was done with ca. 4× MIC. 
The	MIC	of	ampicillin	was	found	to	be	8.88	µg/ml	for	the	K-12	strains	
and 33 µg/m for the CFT073 strains, meaning that treatment with 
100	µg/ml	ampicillin	 (following	reference	Norton	&	Mulvey,	2012)	
represented 11× MIC and 3× MIC, respectively.
After	antibiotic	treatment,	1.5	ml	of	the	samples	was	washed	in	
1 ml of PBS, concentrated in 100 µl of PBS, serially diluted in PBS, 
and	spotted	(10	µl)	on	LB	agar	plates.	Agar	plates	were	incubated	at	
37°C for at least 24 hr, and cfu counts per milliliter were determined 
from spots containing 10 to 100 bacterial colonies. The fraction of 
antibiotic-tolerant cells was calculated as the ratio of the cfu counts 
per milliliter after and before antibiotic treatment. To verify that an-
tibiotic-tolerant cfu represented persister cells, we performed time–
kill curves and confirmed biphasic kinetics of antibiotic killing (see, 
e.g.,	Figure	A2a	in	Appendix	2).
2.9 | Hydrogen peroxide sensitivity assay
The dynamics of hydrogen peroxide sensitivity throughout bacte-
rial growth phases were assayed similarly to the antibiotic toler-
ance assay with the exception that bacteria were challenged with 
10 mM of hydrogen peroxide (H2O2)	(from	10	M	stock;	#cat	31642;	
Sigma) for 30 min instead of antibiotic treatment. Furthermore, ex-
periments were only performed with bacteria grown up to no later 
than late-exponential phase (4 hr after inoculation 1:100 from over-
night culture) because we consistently observed complete tolerance 
to H2O2 in the stationary phase for all bacterial strains. When in-
dicated, the cultures were treated with 20 mM of the antioxidant 
ascorbate	(vitamin	C;	from	1	M	stock;	cat#	A5960)	for	20	min	before	
the challenge with H2O2.
2.10 | Assessment of membrane potential using 
DiOC2(3)
The bacterial membrane potential was assessed using indicator dye 
3,3′-diethyloxacarbocyanine	 iodide	 (DiOC2(3)) as implemented in 
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the BacLight Bacterial Membrane Potential Kit (Invitrogen, Thermo 
Fischer Scientific) according to the manufacturer's recommenda-
tions. The DiOC2(3) dye shows green fluorescence in bacteria at low 
concentrations but becomes more concentrated in cells with larger 
membrane potential, causing it to aggregate and shift the fluores-
cence toward red emission.
Per strain and replicate, 2 μl cells from stationary-phase cul-
tures were inoculated into 2 ml of fresh LB medium in 14-ml Falcon 
round-bottom tubes (Corning) and grown to an OD600 of 0.2 at 37°C 
with	shaking	(180	rpm).	10	μl	culture	was	transferred	to	980	μl fil-
tered phosphate-buffered saline. To each cell solution, 10 μl of 
a 3 mM DiOC2(3) solution was added and cells were stained for 
30 min at room temperature. The assay was verified by depolarizing 
the membrane with the protonophore carbonyl cyanide 3-chloro-
phenylhydrazone (CCCP) at a final concentration of 5 μM. Data were 
recorded	on	a	BD	Biosciences	Accuri	C6	Flow	Cytometer	 (Becton,	
Dickinson, and Company), with emission filters suitable for detecting 
red and green fluorescence. Settings on the flow cytometer were as 
follows: 25'000 recorded events at an FSC threshold of 15.000 and 
medium flow rate. Gating of stained cell population and analysis of 
flow	cytometry	data	were	performed	in	CFlow®	(BD	Accuri).	As	an	
indicator of membrane potential, the ratio of red to green fluores-
cence intensity was calculated.
2.11 | Quantification of ubiquinone 
biosynthesis and levels
Levels of isoprenoid quinones were determined in cell extracts using 
HPLC-ECD-MS (electrochemical detection–mass spectrometry) as 
previously	described	(Hajj	Chehade	et	al.,	2019;	Loiseau	et	al.,	2017).	
The de novo synthesis of ubiquinone (UQ8) and its early biosynthetic 
intermediate octaprenyl-phenol (OPP) was studied by supplement-
ing bacterial cultures with their 13C-labeled precursor 4-hydroxy-
benzoic acid (4-HB) and analyzing the accumulation of 13C label in 
the	molecules	 of	 interest.	 An	 illustration	 of	 the	UQ8 biosynthetic 
pathway in E. coli was included in Figure 5a for clarity.
Bacterial subcultures in 10 ml of M9 medium in Erlenmeyer flasks 
were inoculated 1:100 from dense overnight cultures and agitated 
in a shaking water bath at 37°C/160 rpm to early log phase (2 hr of 
growth for wild-type and ΔpasTI/ΔratAB strains; ca. 108 cfu/ml) or 
late log phase (4 hr of growth for wild-type and ΔpasTI/ΔratAB strains; 
ca. 109 cfu/ml) and then supplemented with 10 µM 13C7-4-HB	(cat#	
587869;	Sigma)	for	an	additional	period	of	30	min.	Subsequently,	cells	
were cooled on ice, harvested by centrifugation, and washed with 
1 ml of cold PBS. The weight of each cell pellet was determined, a 
proportional amount of the UQ10 standard was added, and isoprenoid 
quinones were extracted and analyzed by HPLC-ECD-MS. Single-ion 
monitoring detected the following molecules: 13C6-OPP	 (M+NH4
+), 
m/z 662.0–663.0, 5–10 min, scan time 0.2 s; UQ8 (M+H
+), m/z 727.0–
728.0,	6–10	min,	scan	time	0.2	s;	13C6-UQ8 (M+H
+), m/z 733.0–734.0, 
6–10 min, scan time 0.3 s; and UQ10	 (M+NH4
+),	 m/z	 880.2–881.2,	
10–17 min, scan time 0.2 s. Peak areas were corrected for sample loss 
during extraction based on the recovery of the UQ10 internal standard 
(typically	higher	than	80%)	and	were	then	normalized	to	the	cell's	wet	
weight. The ECD signal of UQ8 was converted into picomoles based on 
a calibration curve obtained with commercial UQ10.
2.12 | Quantification and statistical analysis
Data sets were analyzed by calculating the mean and standard devia-
tion of at least three biological replicates for each experiment. Detailed 
information for each experiment is provided in the figure legends.
3  | RESULTS
3.1 | pasTI does not encode a toxin–antitoxin system
One previous study proposed that the pasTI	locus	encodes	a	new	TA	
system	composed	of	the	PasT	toxin	and	the	PasI	antitoxin	(Norton	
& Mulvey, 2012). However, we did not detect any growth inhibition 
of E. coli CFT073 when pasT was either expressed at physiologically 
relevant levels from a low-copy-number plasmid or overexpressed 
from isogenic plasmids replicating at higher copy numbers (Figure 1). 
Deletion mutants lacking the chromosomally encoded pasTI locus, 
a possible source of experimental interference, also failed to show 
any inhibition of growth upon pasT	 overexpression	 (Figure	 A1a,	
Appendix	 2).	 Similarly,	 the	 expression	 of	pasT failed to inhibit the 
growth of E. coli	K-12	MG1655	(Figure	A1b,	Appendix	2).	No	growth	
inhibition was also observed upon expression of the proposed anti-
toxin pasI	(Figure	A1c,	Appendix	2).	We	therefore	concluded	that	the	
pasTI	locus	is	unlikely	to	encode	a	TA	system.
3.2 | Lack of pasT impairs antibiotic tolerance of 
E. coli CFT073
To gain deeper insight into the role of pasTI in E. coli persister forma-
tion, we monitored the level of antibiotic-tolerant cells throughout 
the different bacterial growth phases as previously described (Harms 
et al., 2017). Interestingly, we observed decreased survival of the 
E. coli CFT073 ΔpasTI mutant when treated with ciprofloxacin com-
pared to the wild-type during exponential growth and over into the 
stationary phase. This defect in survival was caused by a lower level 
of persister cells in the ΔpasTI mutant population (Figure 2a; see also 
Figure	A2a	in	Appendix	2),	and	similar	results	were	obtained	for	treat-
ment	with	the	membrane-targeting	antibiotic	colistin	(Figure	A2b,d,f	
in	Appendix	2).	For	the	β-lactam ampicillin, we observed increased 
levels of tolerant cells for the ΔpasTI mutant, possibly caused by its 
partial growth defect since this class of antibiotics only kills actively 
growing	 cells	 (Figure	A2c,e	 in	Appendix	2).	Conversely,	 no	pheno-
type was observed at any time of the growth curve when comparing 
antibiotic tolerance of E. coli K-12 MG1655 and its ΔratAB derivative 
(Figure	2b;	see	also	Figure	A2a	in	Appendix	2).
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These results were overall consistent with the previous obser-
vation that pasTI is somehow critical for the formation or survival of 
antibiotic-tolerant persister cells in E. coli CFT073 but that ratAB in 
E. coli	K-12	MG1655	is	not	(Norton	&	Mulvey,	2012).	Both	the	pasTI 
and ratAB loci, provided in trans from a low-copy plasmid, as well as 
pasT or ratA alone, could complement the phenotype of decreased 
ciprofloxacin persister levels of E. coli CFT073 ΔpasTI (Figure 2c,d; 
see	also	Figure	A2a	in	Appendix	2).	These	results	demonstrate	that	
the defect of E. coli CFT073 ΔpasTI in persister formation or survival 
is linked to the lack of PasT. Furthermore, they reveal that the dif-
ferential effect of a pasTI/ratAB knockout in the two E. coli strains 
is	not	due	to	differences	between	PasT	and	its	ortholog	RatA.	This	
finding	is	not	unexpected	given	the	near	identity	of	PasT	and	RatA	
protein sequences with two amino acid differences only (S90 and 
D111 in PasT of E. coli	CFT073,	 and	N90	and	E111	 in	E. coli K-12 
MG1655). To clarify whether E. coli CFT073 or K-12 is representa-
tive of enterobacteria in general, we tested the ciprofloxacin tol-
erance phenotype of pasTI mutants constructed in two additional 
pathogenic E. coli strains and the more distantly related Salmonella 
Typhimurium	 (Figure	 A3,	 Appendix	 2).	 Clearly,	pasTI knockouts of 
E. coli O157:H7 strain EDL933 and S. enterica Typhimurium SR-11 
showed decreased levels of ciprofloxacin-tolerant persisters that 
could be complemented by expression of E. coli CFT073 pasT. The 
other tested pathogenic E. coli	 strain	55989	also	showed	 lower	ci-
profloxacin tolerance after pasTI was knocked out, but we cannot 
exclude that this phenotype might be partially caused by decreased 
intrinsic ciprofloxacin resistance of the pasTI mutant in this strain 
(Figure	A3,	Appendix	2).	Taken	together,	these	results	suggest	that	
the phenotypes of E. coli CFT073 ΔpasTI and not of E. coli K-12 
ΔratAB are more broadly representative.
3.3 | E. coli PasT/RatA is the homolog of 
mitochondrial Coq10
The pasT/ratA gene is well conserved among Proteobacteria and not 
always associated with pasI/ratB orthologs (Figure 3), suggesting 
that	PasT/RatA	might	have	a	conserved	housekeeping	function	that	
can be exerted independently of its previously proposed antitoxin 
partner.
Interestingly,	 PasT	 shares	 a	 protein	 domain	 (Pfam:	 Polyketide_
cyc2,	PF10604;	InterPro:	StART	domain,	IPR005031)	and	modest	se-
quence	similarity	to	the	mitochondrial	protein	Coq10	(Figure	A4a/b,	
Appendix	 2;	 Shen	 et	 al.,	 2005;	 Tsui	 et	 al.,	 2019).	 Coq10	has	 been	
studied as an accessory factor of the mitochondrial electron trans-
port chain (ETC), a series of protein complexes that create an elec-
trochemical gradient across a membrane (the “proton-motive force”) 
which	 fuels	 cellular	 ATP	 synthesis	 (Figure	 4a;	 Anraku,	 1988).	 In	
E. coli, electron transport along the ETC involves the electron shuttle 
ubiquinone under aerobic conditions (Sharma, Teixeira de Mattos, 
Hellingwerf, & Bekker, 2012) while two related but distinct mole-
cules, menaquinone and demethylmenaquinone, predominate under 
anaerobic	conditions	(Nitzschke	&	Bettenbrock,	2018	and	literature	
cited therein). Studies on yeast Coq10 indicated that this protein 
might serve as a “lipid chaperone” carrying newly synthesized ubi-
quinone to the respiratory complexes and/or localizing it properly 
within the ETC using a steroidogenic acute regulatory protein-re-
lated	 lipid	 transfer	 (StART)	 domain	 (Figure	 4a;	 Awad	 et	 al.,	 2018;	
Tran & Clarke, 2007). Based on the similarity of the two proteins, 
we	hypothesized	that	PasT/RatA	might	be	the	bacterial	homolog	of	
mitochondrial Coq10 and have a related or even equivalent role in 
cellular respiration.
F I G U R E  1   PasT does not inhibit bacterial growth. Spot assay of E. coli CFT073 harboring isogenic plasmids with different copy number 
encoding either pasT	or	the	well-studied	TA	module	toxin	doc (as positive control) under the control of a Plac promoter on LB agar plates 
containing 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) and repressed on LB agar plates containing 1% w/v d-glucose (see details 
in Materials and Methods). Similar results were obtained for pasT expression in E. coli CFT073 ΔpasTI, E. coli K-12 MG1655, and E. coli K-12 
MG1655 ΔratAB	(Figure	A1a/b	in	Appendix	2).	No	growth	inhibition	was	also	observed	for	the	expression	of	pasI	(Figure	A1c	in	Appendix	2).
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3.4 | E. coli ΔpasTI/ΔratAB mutants display defective 
respiration and modest phenotypes in ubiquinone 
biosynthesis
Yeast	mutants	lacking	coq10 are known to display defective electron 
transport	(Allan	et	al.,	2013;	Cui	&	Kawamukai,	2009),	and	we	there-
fore studied whether ETC functionality is also compromised in E. coli 
mutants	 lacking	 PasT/RatA.	 The	 efficiency	 of	 bacterial	 electron	
transport was assessed using fluorescent indicator dye DiOC2(3) to 
probe the cellular membrane potential. Compared to the parental 
wild-type strains, both pasTI and ratAB mutants revealed a modest 
shift of signal toward the depolarized controls that could be com-
plemented by providing pasT or ratA in trans	(Figure	4b).	As	an	inde-
pendent approach to study the same phenomenon, we compared the 
minimum inhibitory concentrations (MICs) of gentamicin and zeocin 
for growth of the E. coli pasTI and ratAB mutants and their parental 
wild-type	strains	(Figure	4c,d;	see	also	Figure	A5a-c	in	Appendix	2).	
The uptake of gentamicin and zeocin, antibiotics of the aminoglyco-
side and the bleomycin families, is directly dependent on and pro-
portional to the proton-motive force, so that impaired functionality 
F I G U R E  2   PasT is important for the formation or survival of ciprofloxacin-tolerant persisters. (a) Bacterial growth (colony-forming units 
(cfu)/ml; top graph) and dynamics of ciprofloxacin-tolerant cells (tolerant cfu/ml; top graph), as well as the fraction of tolerant cells at each 
data point (bottom graph), were determined for cultures of E. coli CFT073 and CFT073 ΔpasTI over time from inoculation over exponential 
growth into stationary phase. In short, bacteria were cultured for 1 hr, 2 hr, 3 hr, etc., and at each time point, we determined (1) total 
bacterial cfu/ml by direct plating and (2) drug-tolerant cfu/ml by plating after 5 hr of treatment with 10 µg/ml ciprofloxacin (see Materials 
and Methods for details). (b) The same experiment as described in (a) was performed for cultures of E. coli K-12 MG1655 and its ΔratAB 
derivative.	A	similar	drop	of	tolerance	in	E. coli CFT073 ΔpasTI (and the lack thereof in E. coli K-12 MG1655 ΔratAB) was also observed for 
treatment with the membrane-targeting antibiotic colistin but not with the β-lactam	ampicillin	(Figure	A2b/c	in	Appendix	2).	Similar	results	
as obtained with E. coli CFT073 and its ΔpasTI mutant in (a) were also obtained with different pathogenic E. coli strains and Salmonella 
Typhimurium	(Figure	A3a	in	Appendix	2).	(c)	Fractions	of	tolerant	cells	for	cultures	of	E. coli CFT073 ΔpasTI harboring complementation 
plasmids encoding pasTI or ratAB as well as wild-type and ΔpasTI carrying the empty vector (ev) were determined as shown in (a). (d) The 
fraction of tolerant cells at 5 hr after inoculation was determined for cultures of E. coli CFT073 ΔpasTI harboring complementation plasmids 
encoding pasT, ratA, or ratB. Time–kill curves of all strains included in (a-d) sampled at this time point showed biphasic killing, demonstrating 
that	the	differences	in	surviving	cfu/ml	reflect	different	levels	of	persister	cells	(Figure	A2a	in	Appendix	2).	All	data	points	in	(a-d)	represent	
the mean of results from at least three independent experiments, and error bars indicate standard deviations
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of the ETC results in an increased MIC of these antibiotics (Krause, 
Serio, Kane, & Connolly, 2016; Miller, Edberg, Mandel, Behar, & 
Steigbigel,	 1980;	 Søballe	&	Poole,	 2000).	We	 indeed	observed	el-
evated MICs of both drugs for the pasTI and ratAB mutants that 
could be complemented with pasT or ratA but not ratB (Figure 4c,d; 
see	also	Figure	A5a-c	in	Appendix	2).	Taken	together,	these	results	
suggest a clear but modest decrease in membrane polarization as a 
consequence of defective electron transport for both E. coli CFT073 
ΔpasTI and E. coli K-12 MG1655 ΔratAB mutants. Similar results were 
obtained with wild-type and ΔpasTI variants of different pathogenic 
E. coli/S. enterica	strains	(Figure	A5d/e	in	Appendix	2).
To study the role of ubiquinone in these phenotypes, we quan-
tified the total levels of ubiquinone and biosynthetic intermediates 
as well as the de novo biosynthesis of ubiquinone in E. coli ΔpasTI/
ΔratAB mutants (Figure 5a-d). Previous work found that yeast coq10 
mutants show decreased efficiency of ubiquinone biosynthesis spe-
cifically in exponential growth but have largely normal overall lev-
els	 of	 ubiquinone	 in	 their	mitochondria	 (Allan	 et	 al.,	 2013;	 Barros	
et al., 2005). Similarly, we saw no differences in total ubiquinone 
content when comparing E. coli ΔpasTI/ΔratAB mutants to their pa-
rental wild-type strains (Figure 5b). However, we indeed found a de-
crease in ubiquinone precursor levels for both ΔpasTI and ΔratAB 
mutants during the exponential growth phase and a mild defect 
in the de novo biosynthesis of ubiquinone specifically for CFT073 
ΔpasTI in early log phase that could be complemented by pasT/ratA 
(Figure 5c/d).
3.5 | E. coli ΔpasTI/ΔratAB mutants display increased 
susceptibility to oxidative stress
Beyond defects in electron transport and log-phase ubiquinone bio-
synthesis, yeast mutants lacking Coq10 are known to be hypersensi-
tive	to	oxidative	stress	(Allan	et	al.,	2013;	Cui	&	Kawamukai,	2009).	
This phenomenon is consistent with our observation that E. coli 
and Salmonella pasTI and ratAB mutants grow like their parental 
wild-types in the absence of oxygen but show a small-colony phe-
notype	under	aerobic	conditions	 (Figure	6a;	see	also	Figure	A6a-b	
in	Appendix	2).	Similar	phenotypes	are	typical	for	bacterial	mutants	
with defects in respiration and/or ubiquinone biosynthesis and have 
also been described for the pasT knockout of E. coli CFT073 in pre-
vious	 work	 (Aussel	 et	 al.,	 2014;	 Day,	 2013;	 Koskiniemi,	 Pranting,	
Gullberg,	Näsvall,	&	Andersson,	2011;	Norton	&	Mulvey,	2012;	Poon	
et al., 2000; Proctor et al., 2014; Xia et al., 2017). Complementation 
with pasT or ratA, but not ratB, provided on a low-copy plasmid 
enabled the growth of E. coli pasTI and ratAB mutants to normal 
colony	size	under	aerobic	conditions	(Figure	6b,c;	see	Figure	A6a	in	
Appendix	2).
We further compared the sensitivity of E. coli CFT073 ΔpasTI and 
its parental wild-type to hydrogen peroxide (H2O2) as an exogenous 
source of oxidative damage (Figure 7a). Similar to previous observa-
tions with yeast coq10 mutants (Cui & Kawamukai, 2009), the pasT 
knockout was hypersensitive to oxidative damage which could be 
abolished by pretreating the cultures with the potent antioxidant 
ascorbic	 acid	 (vitamin	C;	 Figure	 7b	 and	 Figure	A6c-e	 in	Appendix	
2). The H2O2 sensitivity of E. coli CFT073 ΔpasTI could also be com-
plemented in trans by pasT/ratA, but not ratB, expressed from their 
promoter (Figure 7c). Taken together, these results presented in 
Figures	4-7	establish	that	the	lack	of	PasT	or	RatA	in	E. coli causes 
similar phenotypes as known for yeast coq10 mutants.
3.6 | PasT deficiency in E. coli can be functionally 
complemented with human mitochondrial Coq10
Given the high conservation of respiratory electron transport in-
cluding the electron shuttle ubiquinone, we wondered whether 
PasT/RatA	 knockout	 phenotypes	 could	 be	 heterologously	 com-
plemented by other bacterial or even mitochondrial homologs. 
Previous work had already shown that the alphaproteobacterial PasT 
homolog CC1376 of C. crescentus and human Coq10 can comple-
ment the S. cerevisiae Δcoq10	phenotypes	(Allan	et	al.,	2013;	Barros	
F I G U R E  3   pasT and, to a lesser extent, pasI are widely conserved among Proteobacteria. The genomic organization of pasT (green)/pasI 
(orange)	loci	is	shown	for	representative	Proteobacteria.	Genes	conserved	in	two	or	more	organisms	are	shown	in	blue.	A	list	of	full	strain	
names	and	genome	accessions	used	for	this	synteny	analysis	is	found	in	Table	A4	(Appendix	1).
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et al., 2005; Cui & Kawamukai, 2009). Remarkably, both CC1376 and 
human mitochondrial Coq10 could also complement all phenotypes 
of	RatA/PasT	 knockout	mutants	 in	E. coli: small colony size under 
aerobic condition, increased MIC of gentamicin/zeocin, defect of 
E. coli CFT073 in antibiotic tolerance, and, at least to some extent, 
H2O2	sensitivity	(Figure	8a-d	and	Figure	A6f	in	Appendix	2).	These	
results	show	that	RatA/PasT	and	CC1376	or	Coq10	are	not	merely	
homologs	 (Figure	 A4a/b	 in	 Appendix	 2)	 but	 seem	 to	 also	 share	 a	
function linked to respiratory electron transport that is conserved 
from bacteria to humans.
4  | DISCUSSION
4.1 | No evidence for links between PasT and PasI 
or a common function as a TA system
Our study had initially been inspired by previous work proposing 
that	PasT	is	a	TA-encoded	toxin	that	inhibits	ribosome	assembly	and	
somehow contributes to persister cell formation of uropathogenic 
E. coli	(Norton	&	Mulvey,	2012;	Zhang	&	Inouye,	2011).	Given	recent	
debates	about	the	role	of	TA	systems	in	antibiotic	tolerance	of	E. coli, 
F I G U R E  4   E. coli CFT073 ΔpasTI and E. coli MG1655 ΔratAB mutants have a defective electron transport chain (ETC). (a) The figure 
illustrates how electrons (e−)	flow	in	the	mitochondrial	electron	transport	chain	(ETC)	from	complex	I	(NADH	dehydrogenase)	or	complex	II	
(succinate dehydrogenase) to complex III (cytochrome bc1 complex) via membrane-bound ubiquinone (commonly abbreviated as Q). Then, 
electrons transit via cytochrome C molecules and reach complex IV (cytochrome c oxidase) where they reduce dioxygen into water. Electron 
transfer is coupled to the active export of protons through the ETC complexes. The overall setup of this ETC is related in mitochondria 
and E. coli, but E. coli can also respire anaerobically by using alternative terminal electron acceptors and the dedicated anaerobic electron 
carriers menaquinone and demethylmenaquinone instead of ubiquinone. Studies on the mitochondrial ETC in yeast suggested that Coq10 
is a “lipid chaperone” involved in the delivery of ubiquinone (synthesized by the multi-subunit protein complex Q) to its sites of function 
and/or	proper	localization	at	the	sites	of	function	(recently	reviewed	by	Awad	et	al.,	2018;	Stefely	&	Pagliarini,	2017;	Tran	&	Clarke,	2007).	
(b) The membrane potential of different E. coli samples was assessed using the DiOC2(3) dye in a way that a decrease in red/green ratio is 
indicative of depolarization (see Materials and Methods). Results were compared to values obtained with the uncoupler CCCP (complete 
depolarization) and the E. coli K-12 ubiA mutant (unable to synthesize ubiquinone; Pelosi et al., 2019). Both ratAB and—more pronounced—
pasTI knockouts showed a decrease in the signal that was less strong than the effect of a ubiA knockout and could be complemented by 
ratA/pasT. (c, d) Minimum inhibitory concentrations (MIC) of E. coli CFT073 ΔpasTI for gentamicin (c) and zeocin (d) were determined by broth 
dilution assays. The bacteria carried either an empty vector (ev) or complementation plasmids encoding pasTI, ratAB, pasT, ratA, or ratB. For 
gentamicin,	the	result	of	one	representative	experiment	is	shown	(additional	independent	replicates	in	Figure	A5a	in	Appendix	2).	Similar	
results were obtained for E. coli K-12 MG1655 ΔratAB.	(Figure	A5b/c	in	Appendix	2).	Unless	specified	otherwise,	data	points	represent	the	
mean of results from three independent experiments, and error bars indicate standard deviations.
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this	was	a	very	interesting	result	(Goormaghtigh	et	al.,	2018;	Harms	
et al., 2017; Shan et al., 2017). However, we found no evidence for 
a	link	of	PasT	to	either	TA	systems	or	ribosomes.	Consistently,	the	
data of a previous study also showed that expression of the PasT/
RatA	 ortholog	 of	 Salmonella Typhimurium did not affect bacterial 
growth	(Lobato-Marquez,	Moreno-Cordoba,	Figueroa,	Diaz-Orejas,	
& Garcia-del Portillo, 2015). The discrepancy between our results 
and earlier work reporting growth inhibition upon PasT expression 
may be explained by the very high overexpression of protein con-
structs in previous studies that is prone to interfere with cellular 
physiology. Consistently, severe overexpression of coq10 in yeast in-
hibited cellular growth by interfering with mitochondrial respiration 
(Zampol	et	al.,	2010).
Our study also did not find evidence for a functional link be-
tween PasT and PasI, because phenotypes observed with ΔpasTI 
mutants could always be complemented by pasT and its homologs 
alone but never by its proposed antitoxin partner. Consistently, only 
pasT genes of beta- and gammaproteobacteria are accompanied by a 
pasI gene while solitary pasT (including mitochondrial coq10) is much 
more abundant (Figure 3; Shen et al., 2005; Tsui et al., 2019). Future 
studies could therefore explore whether PasI might be an acces-
sory factor to PasT that constitutes an evolutionary innovation in 
beta- and gammaproteobacteria or whether pasI	is	just	a	functionally	
unrelated protein that these lineages acquired and encoded next to 
pasT merely by chance.
4.2 | Unification of the PasT/Coq10 family of StART 
domain proteins
Though we cannot exclude that PasT has a moonlighting function 
linked to ribosome assembly, multiple observations suggest that 
PasT is the bacterial equivalent of its mitochondrial homolog Coq10 
that acts as an accessory factor in the ubiquinone-dependent ETC: 
E. coli	mutants	 lacking	PasT/RatA	display	phenotypes	linked	to	de-
fective ubiquinone-dependent electron transport that are similar to 
F I G U R E  5   Direct measurements of ubiquinone levels and biosynthesis. (a) Schematic summary of the ubiquinone (UQ8) biosynthetic 
pathway in E. coli.	The	precursor	of	4-hydroxybenzoic	acid	(4-HB)	is	prenylated	by	UbiA	and	decarboxylated	by	UbiD	to	form	the	early	
intermediate octaprenyl-phenol (OPP). Subsequent modifications of the aromatic ring by Ubi enzymes (UbiI, UbiG, UbiH, UbiE, and UbiF) 
yield	ubiquinone	8	(UQ8). When 
13C7-4-HB is added to cultures to evaluate de novo synthesis of UQ, 
13C6-OPP and 
13C6-UQ8 are formed 
(13C carbon atoms represented in green). (b) Total ubiquinone (UQ8) content (sum of 
13C6-UQ8 and unlabeled ubiquinone UQ8) was assessed 
after HPLC-ECD-MS analysis (see Materials and Methods) for early and late log-phase cultures of E. coli CFT073, K-12 MG1655, their ΔpasTI/
ΔratAB mutant derivatives, and the complemented strains. (c) The content of 13C6-OPP (octaprenyl-phenol, an early intermediate of the 
UQ8 pathway, see (a)) is reported for the same strains. (d) The plot shows the fraction of 
13C6-UQ8 over total UQ8 and is thus informative 
about the de novo biosynthesis of UQ8	for	the	same	strains	as	in	(b)	and	(c).	All	data	points	represent	the	mean	of	results	from	four	
independent	experiments,	and	error	bars	indicate	standard	deviations.	An	E. coli K-12 MG1655 ubiX mutant was used as a negative control 
in	these	experiments	since	UbiX	is	required	for	ubiquinone	biosynthesis	by	producing	a	crucial	cofactor	for	UbiD	(Aussel	et	al.,	2014;	White	
et	al.,	2015;	see	also	in	(a)).	ev	=	empty	vector	pNDM220,	n.d.	=	not	detected
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phenotypes observed for coq10 mutants (Figures 4-7), and these phe-
notypes	can	be	largely	complemented	by	human	Coq10	(Figure	8).	
Consistently, a prediction of potential functional partners for PasT/
RatA	using	STRING	 (https://strin	g-db.org/;	Szklarczyk	et	al.,	2018)	
retrieved many proteins involved in ubiquinone biosynthesis and 
the	ETC	but	no	ribosomal	proteins	(Figure	A4c	in	Appendix	2).	From	
these	 results,	we	 therefore	 conclude	 that	 PasT/RatA	 are	 not	 only	
homologous to Coq10 but at least to large extent functionally equiv-
alent as “lipid chaperones” that arrange the utilization of ubiqui-
none	in	the	ETC	(recently	reviewed	by	Awad	et	al.,	2018;	Stefely	&	
Pagliarini, 2017).
These findings close one of the multiple gaps in our understand-
ing of the electron transport chain and the functionality of ubiqui-
none that are widely conserved and thus relevant both for human 
diseases and—given the broad conservation of pasT among patho-
genic	 Proteobacteria	 (Figure	 3)—for	 antibiotic	 treatment	 (Aussel	
et	al.,	2014;	Hirose	et	al.,	2019;	Stefely	&	Pagliarini,	2017).	Notably,	
eukaryotic ubiquinone biosynthesis and respiratory electron trans-
port chain are mitochondrial pathways that have been acquired by 
the eukaryotic lineage from the primordial bacterial endosymbiont 
during its evolution from a proteobacterium into extant mitochon-
dria	 (Andersson	et	al.,	1998;	Stefely	&	Pagliarini,	2017).	We	there-
fore anticipate that future studies on the PasT/Coq10 family might 
use the technically highly accessible E. coli system to unravel the mo-
lecular function of these proteins in ubiquinone-dependent respira-
tion that seems to be conserved from bacteria to humans.
4.3 | Links between PasT, electron transport, and 
oxidative stress
E. coli ΔratAB/ΔpasTI mutants display several phenotypes linked to 
oxidative stress sensitivity or redox balance (Figure 4 and Figure 6/
Figure 7) that correlates with modest defects in exponential-phase 
ubiquinone biosynthesis as also previously observed for yeast coq10 
mutants (see above). However, it is not clear how defective respira-
tion causes these phenotypes or what is the molecular function of 
Coq10	(Allan	et	al.,	2013;	Awad	et	al.,	2018;	Barros	et	al.,	2005;	Cui	&	
Kawamukai, 2009; Stefely & Pagliarini, 2017; Tsui et al., 2019). In this 
regard,	our	study	moves	the	understanding	of	PasT/RatA	roughly	to	
the point of how far the field understands Coq10.
Notably,	the	mild	defect	of	E. coli CFT073 ΔpasTI in ubiquinone 
biosynthesis (Figure 5c/d) was too weak to affect steady-state ubi-
quinone levels (Figure 5a). It therefore cannot explain the multiple 
phenotypes of E. coli ΔpasTI/ΔratAB mutants that are linked to de-
fective aerobic respiration given that, for example, the considerable 
reduction of ubiquinone levels in an E. coli ubiI mutant (ca. 15% of 
wild-type) still enables normal respiration (Pelosi et al., 2016). These 
strong	 pleiotropic	 phenotypes	 of	 PasT/RatA	 deficiency	 (and	 the	
lack of Coq10) are therefore likely caused by problems linked to the 
proposed role of these proteins as “lipid chaperones” that facilitate 
the implementation of ubiquinone at the electron transport chain 
(recently	reviewed	by	Awad	et	al.,	2018;	Stefely	&	Pagliarini,	2017).	
Consequently, the observed phenotypes in ubiquinone biosynthesis 
F I G U R E  6   Lack of pasT/ratA causes 
a small-colony phenotype under aerobic 
conditions. (a) Cultures of E. coli CFT073 
wild-type, E. coli K-12 MG1655 wild-type, 
and their ΔpasTI/ΔratAB derivatives were 
diluted and spotted on LB agar plates 
incubated either in the presence (left) 
or absence (right) of oxygen. d-glucose 
(1% w/v) was added as a fermentable 
carbon source to LB agar plates incubated 
anaerobically (see Materials and Methods). 
(b, c) Spot assay of E. coli CFT073 ΔpasTI 
(b) or E. coli K-12 MG1655 ΔratAB (c) 
carrying the empty vector (ev) or different 
complementation plasmids was spotted 
on LB agar plates to visualize differences 
in colony size. Similar results as shown 
in (a-c) were also obtained with different 
pathogenic E. coli strains and Salmonella 
Typhimurium	(Figure	A6a/b	in	Appendix	2)
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might rather be downstream consequences—maybe via a feedback 
mechanism—of improperly utilized ubiquinone.
In general, impaired aerobic respiration often causes growth 
defects and a small-colony phenotype specifically under aerobic 
conditions	 (Aussel	et	al.,	2014;	Day,	2013;	Koskiniemi	et	al.,	2011;	
Poon et al., 2000; Proctor et al., 2014; Xia et al., 2017). On the one 
hand, this observation could be explained by the poor energy me-
tabolism of these mutants due to their limited ability to use oxygen 
as a terminal electron acceptor, while under anaerobic conditions 
other quinone electron shuttles serve other terminal acceptors or 
merely fermentation takes place instead. On the other hand, these 
observations could be explained as a consequence of reactive oxy-
gen species (ROS) sensitivity and/or production. Consistently, E. coli 
K-12 defective for ubiquinone production grows poorly under aer-
obic	conditions	where	it	shows	signs	of	oxidative	stress	(Nitzschke	
&	 Bettenbrock,	 2018),	 and	 similar	 observations	 have	 been	 made	
for a yeast coq10 mutant (Cui & Kawamukai, 2009). These results 
could be explained by the pro- and antioxidant activities of differ-
ent forms of ubiquinone, but the details of this relationship have not 
been	resolved	(Wang	&	Hekimi,	2016).	Also,	defects	in	the	electron	
transport chain cause leakage of electrons and uncontrolled forma-
tion of ROS that damages cellular macromolecules, a problem in-
herent to respiration, and linked to many human diseases (Jastroch, 
Divakaruni,	Mookerjee,	Treberg,	&	Brand,	2010).	We	anticipate	that	
future studies unraveling the precise biological function of PasT/
Coq10 in the context of ubiquinone-dependent respiration will also 
reveal how the lack of its activity is linked to oxidative stress and 
cellular redox balance in bacteria and humans.
4.4 | PasT highlights the importance of electron 
transport for bacterial persister cells
The initial focus of our study was to understand the specific defect 
of uropathogenic E. coli CFT073 lacking pasTI in the formation or 
survival	of	persister	cells	 (Norton	&	Mulvey,	2012).	We	readily	 re-
produced this phenotype in E. coli CFT073 itself and different patho-
genic E. coli strains as well as Salmonella Typhimurium (Figure 2 as 
well	as	Figures	A2	and	A3	in	Appendix	2).	However,	our	results	also	
showed	that	PasTI	is	not	just	a	genetic	switch	controlling	transition	
into	dormancy	as	a	TA	module	would	supposedly	be.	Instead,	PasT	
seems to be deeply wired into bacterial redox balance and energy 
metabolism through its role as a facilitator of ubiquinone-depend-
ent respiration (Figure 9). The link of PasT to antibiotic tolerance is 
therefore likely indirect and mediated through broad distortions of 
bacterial physiology caused by defective aerobic respiration.
A	general	 link	 between	persister	 formation	 and	ETC	 function-
ality is well established; various mutations in ETC components can 
show both increased and decreased levels of persisters (Harms 
et al., 2016; Shan, Lazinski, Rowe, Camilli, & Lewis, 2015; Van den 
F I G U R E  7   pasT/ratA deficiency causes hypersensitivity to redox stress and oxidative damage in E. coli. (a) Dynamics of colony-forming 
units (cfu/ml: top graph; a fraction of survivors: bottom graph) before and after treatment with hydrogen peroxide (H2O2) for E. coli CFT073 
wild-type/ΔpasTI over time after inoculation from stationary phase into fresh medium (see Materials and Methods). (b) The fraction of cells 
surviving H2O2 treatment 2 hr after inoculation from the stationary phase was determined for cultures of E. coli CFT073 wild-type/ΔpasTI 
with or without pretreatment with the antioxidant vitamin C (ascorbate). Similar results as shown in (a) and (b) for E. coli CFT073 wild-type/
ΔpasTI were also obtained for E. coli K-12 MG1655 wild-type/ΔratAB	(Figure	A6d/e	in	Appendix	2).	(c)	The	fraction	of	cells	surviving	H2O2 
treatment 2 hr after inoculation from stationary phase was determined for cultures of E. coli CFT073 wild-type/ΔpasTI carrying either the 
empty vector (ev) or different complementation plasmids. We could not assay the complementation of H2O2 sensitivity for E. coli K-12 
MG1655 ΔratAB because, curiously, already the empty vector caused a strong decrease in H2O2	sensitivity	of	this	strain	(Figure	A6d	in	
Appendix	2).	All	data	points	in	(a-c)	represent	the	mean	of	results	from	at	least	three	independent	experiments,	and	error	bars	indicate	
standard deviations
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Bergh et al., 2016). However, the physiological basis of this link and 
the underlying molecular mechanisms are poorly understood. One 
possibility is that the ETC could modulate persister levels by affect-
ing	ATP	production	since	persister	formation	can	be	associated	with	
decreased	ATP	levels	(Shan	et	al.,	2017).	However,	impaired	electron	
transport upon PasT deficiency should then rather cause increased 
persister	formation	by	limiting	cellular	ATP	production.	Alternatively,	
it has been hypothesized repeatedly that bacterial killing by various 
antibiotics is causally linked to the generation of ROS by a hyperacti-
vated ETC in response to metabolic perturbations (Kohanski, Dwyer, 
&	Collins,	2010;	Yang,	Bening,	&	Collins,	2017),	though	these	ideas	
have been disputed by others (Keren, Wu, Inocencio, Mulcahy, & 
Lewis, 2013; Liu & Imlay, 2013). This view would suggest that the 
decreased antibiotic tolerance upon pasT deficiency is linked to 
drug-induced ROS production and ultimately rooted in a general hy-
persensitivity to ROS. Consistently, mechanisms involved in reducing 
oxidative stress and increasing ROS detoxification have been linked 
previously to persister survival in E. coli CFT073 and other bacteria 
(Molina-Quiroz,	Lazinski,	Camilli,	&	Levy,	2016;	Nguyen	et	al.,	2011).
Critically, none of these hypotheses can explain why the 
four E. coli strains investigated in this work as well as Salmonella 
Typhimurium share most phenotypes linked to pasT/ratA 
deficiency except for the persister defect that is specifically absent 
in the E. coli K-12 MG1655 laboratory strain (Figure 2/Figure 4/
Figure	6/Figure	7	and	Figure	A2/Figure	A3/Figure	A5/Figure	A6	
in	Appendix	2).	Also,	the	E. coli K-12 ΔratAB mutant did not show 
the modest defect in exponential-phase ubiquinone biosynthesis 
that was readily apparent for E. coli CFT073 ΔpasTI (Figure 5d). 
Before testing the other strains beyond E. coli K-12 and CFT073, 
we initially suspected that the widespread use of strains carrying 
rpoS loss-of-function alleles (rpoSam) as E. coli CFT073 “wild-type” 
might explain the increased sensitivity of this strain compared 
to K-12 MG1655 (Hryckowian, Baisa, Schwartz, & Welch, 2015; 
Hryckowian & Welch, 2013) since RpoS is a central player in 
E. coli	stress	responses	(Battesti,	Majdalani,	&	Gottesman,	2011).	
Targeted sequencing of rpoS indeed confirmed that our E. coli 
CFT073 strain carried the rpoSam allele. However, control exper-
iments with a variant carrying intact rpoS found no differences 
in antibiotic tolerance and all other phenotypes to our original 
data beyond a change in the dynamics of H2O2 survival that in this 
strain look much more similar to E. coli	K-12	MG1655	(Figure	A7	
in	Appendix	2).	These	results	suggest	that	RpoS-controlled	stress	
responses can buffer against some of the distortions of bacterial 
physiology that are caused by a lack of PasT but do not explain 
F I G U R E  8   CC1736 of Caulobacter crescentus and human mitochondrial Coq10 can functionally complement the E. coli CFT073 ΔpasTI 
mutant. (a) The colony sizes of E. coli CFT073 strain harboring the empty vector (ev) or complementation plasmids encoding pasT homolog 
cc1736 from C. crescentus or human coq10 under Plac control were analyzed on LB agar plates supplemented with 1% d-glucose (repressing 
expression of complementation constructs) or 1 mM IPTG (inducing expression of complementation plasmids). Similar results were obtained 
with E. coli K-12 MG1655 ΔratAB	(Figure	A6f	in	Appendix	2).	(b)	Minimum	inhibitory	concentration	(MIC)	of	these	strains	for	gentamicin	
(top) and zeocin (bottom) was determined via broth dilution assays. For gentamicin, results of one representative experiment are presented; 
additional independent replicates and similar data obtained with E. coli K-12 MG1655 ΔratAB	are	shown	in	Appendix	2	(Figure	A5a-c).	(c)	
Antibiotic	tolerance	assays	were	performed	like	those	shown	in	Figure	2,	and	the	fraction	of	ciprofloxacin-tolerant	cells	5	hr	after	inoculation	
was determined for cultures of E. coli CFT073 ΔpasTI harboring complementation plasmids encoding cc1736 or coq10 or the empty vector 
(ev). Time–kill curves at this time point showed biphasic killing, revealing that the differences in antibiotic tolerance reflect different levels of 
persister	cells	(Figure	A2a	in	Appendix	2).	(d)	The	sensitivity	of	E. coli CFT073 ΔpasTI to treatment with hydrogen peroxide (H2O2) 2 hr after 
inoculation was determined for strains carrying cc1736 or coq10 complementation plasmids or the empty vector (ev) as shown in Figure 7c. 
Unless indicated otherwise, all data points in (a-d) represent the mean of results from at least three independent experiments and error bars 
indicate standard deviations. In all experiments, the Plac promoter on all plasmids was induced during overnight cultures and throughout the 
experiment by supplementing culture media with 1 mM IPTG.
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the severe defect of E. coli CFT073 ΔpasTI in antibiotic tolerance. 
Given that this defect and all other phenotypes are also shared 
by different pathogenic E. coli as well as Salmonella Typhimurium 
(Figure	A3/Figure	A5/Figure	A6	 in	Appendix	2),	 it	 is	 likely	 to	be	
more representative of enterobacteria while the divergent behav-
ior of E. coli K-12 MG1655 might be related to one or more fea-
tures of the peculiar physiology of this laboratory-adapted strain 
(Hobman, Penn, & Pallen, 2007).
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Strain Genotype Source/description
CF323 Escherichia coli K-12 MG1655: F– 
λ–ilvG– rfb-50 rph-1
Wild-type strain; Gerdes laboratory 
collection
EG94 E. coli K-12 MG1655 ΔhipAB::FRT 
pBAD33	ParaB:: SD4 atg hipA
MG1655 hipAB::FRT	harboring	pBAD33	
ParaB:: SD4 atg hipA (Germain 
et al., 2013)
CF083 E. coli K-12 MG1655 ΔratAB This study; derivative of E. coli K-12 
MG1655 with scarless deletion of 
ratAB
CF002 Escherichia coli CFT073: hly+ pap1+ 
sfa1+ pil1+ (rpoSam)
Obtained	from	Anders	Løbner-Olesen;	
a	5	bp	duplication	(TAGAG)	at	the	3′	
end of c3307 ORF causes a frameshift 
and premature amber stop codon in 
rpoS as reported earlier (Hryckowian 
et al., 2015); used throughout most of 
this study
CF069 E. coli CFT073 ΔpasTI (rpoSam) This study; derivative of CF002 with 
scarless deletion of pasTI; used 
throughout most of this study
CF370 E. coli CFT073 (intact rpoS) E. coli CFT073 wild-type with intact 
rpoS; obtained from Daniel R. Brown, 
Imperial College London (UK)
CF378 E. coli CFT073 ΔpasTI (intact rpoS) This study; derivative of CF370 with 
scarless deletion of pasTI
ALO3978 E. coli GM9255 EDL933 (933w 
Δstx2AB::kan)
Anders	Løbner-Olesen	laboratory	
collection; attenuated version of 
E. coli O157:H7 strain EDL933 with 
deletion of the Shiga toxin (Marinus & 
Poteete, 2013)
CF583 EDL933 ΔpasTI This	study;	derivative	of	ALO3978	with	
scarless deletion of pasTI
CF555 E. coli	55989 Obtained	from	Karen	A.	Krogfelt,	
Roskilde University (DK)
CF598 E. coli	55989	ΔpasTI::FRT This study; derivative of CF555 after 
disruption of pasTI locus with an 
FRT-kmFRT selectable cassette, then 
flipped out
CF557 Salmonella enterica serovar enterica 
str. SR-11
Obtained	from	Karen	A.	Krogfelt,	
Roskilde University (DK)
CF587 SR-11 ΔpasTI This study; derivative of CF557 with 
scarless deletion of pasTI
CF574 E. coli K-12 MG1655 ΔubiA::cat Pierrel laboratory collection (Pelosi 
et al., 2019)
CF575 E. coli K-12 MG1655 ΔubiX::km Pierrel laboratory collection (Pelosi 
et al., 2019)
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APPENDIX 2
TA B L E  A 2   List of all plasmids used in this study
Identifier Plasmid Genotype/selection Source/description/construction
n.a. pNDM220 mini-R1 ori; bla; lacIq; Plac promoter. 
Amp	30	µg/ml
Gerdes laboratory collection
n.a. pBAD33 pA15	ori;	cat; araC; ParaB promoter. 
Cam 25 µg/ml
Gerdes laboratory collection
n.a. pWRG99 TS ori; bla; ParaB promoter; λred. 
Amp	100	µg/ml
(Blank et al., 2011); recombineering plasmid
n.a. pKO4/pELO4 Cam 25 µg/ml (Lee et al., 2001); template plasmid for 
amplification of the cat-sacB cassette for 
recombineering
n.a. pKM208 TS ori; bla; Plac promoter; λred	Amp	
100 µg/ml
(Murphy & Campellone, 2003); 
recombineering plasmid
n.a. pCP20 TS ori; bla;	Amp	100	µg/ml Gerdes laboratory collection; plasmid used 
to flip out the resistance cassette upon 
expression of the flippase (FLP) at 30°C
n.a. pKD3 Amp	30	µg/ml;	Cam	25	30	µg/ml Gerdes laboratory collection; template 
plasmid for amplification of the FRT-cat-
FRT cassette for recombineering
n.a. pKD13 Amp	30	µg/ml;	Km	25	30	µg/ml Gerdes laboratory collection; template 
plasmid for amplification of the FRT-km-
FRT cassette for recombineering
n.a. pAH186_ColE1 ColE1 ori; bla; lacIq; Plac promoter. 
Amp	100	µg/ml
This	study;	derivative	of	pNDM220	with	
ColE1 ori (copy number 15-20) instead 
of mini-R1; the ColE1 ori was amplified 
from pBR322 (our collection) with primers 
prAH1206/prAH1207,	and	a	fragment	
comprising bla-lacIq-Plac was amplified 
from	pNDM220	with	primers	prAH1202/
prAH1203;	the	PCR	products	were	ligated	
after	restriction	digest	with	NsiI	and	
HindIII
n.a. pAH186_SC101 SC101 ori; bla; lacIq; Plac promoter. 
Amp	100	µg/ml
This	study;	derivative	of	pNDM220	with	
SC101 ori (copy number ~5) instead of 
mini-R1; the SC101 ori was amplified 
from	pUA139	(Zaslaver	et	al.,	2006)	with	
primers	prAH1204/prAH1205,	and	a	
fragment comprising bla-lacIq-Plac was 
amplified	from	pNDM220	with	primers	
prAH1202/prAH1203;	the	PCR	products	
were ligated after restriction digest with 
NsiI	and	HindIII
Inducible pasT 
(low copy)
pCF001_pasT_v1 Derivative	of	pNDM220	encoding	
pasT.	Amp	30	µg/ml
This study; the pasT ORF was amplified 
from E. coli CFT073 with a strong RBS 
and	a	GTG	SC	(AGGAGAaacaattttGTG)	
using primers prCF070/prCF071 and 
ligated	into	pNDM220	downstream	Plac 
after digestion of backbone and insert 
with BamHI/EcoRI. The GTG has been 
converted	into	ATG	by	site-directed	
mutagenesis using primers prCF291/
prCF292. IPTG induction of pasT 
expression.
(Continues)
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Identifier Plasmid Genotype/selection Source/description/construction
Inducible pasT 
(high copy)
pAH186_ColE1_pasT_v1 Derivative	of	pAH186_ColE1	
encoding pasT.	Amp	100	µg/ml
This study; the pasT ORF was amplified 
from E. coli CFT073 with a strong RBS 
and	a	GTG	SC	(AGGAGAaacaattttGTG)	
using primers prCF070/prCF071 and 
ligated	into	pAH186_ColE1	downstream	
Plac after digestion of backbone and 
insert with BamHI/EcoRI. The GTG has 
been	converted	into	ATG	by	site-directed	
mutagenesis using primers prCF291/
prCF292. IPTG induction of pasT 
expression
Inducible pasT 
(medium 
copy)
pAH186_SC101_pasT_v1 Derivative	of	pAH186_SC101	
encoding pasT.	Amp	100	µg/ml
This study; the pasT ORF was amplified 
from E. coli CFT073 with a strong RBS 
and	a	GTG	SC	(AGGAGAaacaattttGTG)	
using primers prCF070/prCF071 and 
ligated	into	pAH186_SC101	downstream	
Plac after digestion of backbone and 
insert with BamHI/EcoRI. The GTG has 
been	converted	into	ATG	by	site-directed	
mutagenesis using primers prCF291/
prCF292. IPTG induction of pasT 
expression
pdoc pAH154_doc_v2 Derivative	of	pNDM220	encoding	
doc.	Amp	30	µg/ml
This study; the ORF of doc was amplified 
from bacteriophage P1vir with a weak 
RBS	(ATTCCTCCaacaattttATG)	using	
primers	prAH1542/prAH1541	and	
ligated	into	pNDM220	downstream	Plac	
after digestion of backbone and insert 
with KpnI/XhoI. IPTG induction of doc 
expression
ppasTI pCF006_pasTI_v1 Derivative	of	pNDM220	encoding	
pasTI.	Amp	30	µg/ml
This	study;	pasTI	operon	including	≈300	bp	
upstream was amplified from E. coli 
CFT073 using primers prCF222/prCF223 
and	ligated	into	pNDM220	after	digestion	
of backbone and insert with BamHI/EcoRI. 
V1	=	strong	SD	and	original	SC	(ATG).	
Expression of pasTI under endogenous 
transcriptional control
pratAB pCF006_ratAB_v1 Derivative	of	pNDM220	encoding	
ratAB.	Amp	30	µg/ml
This	study;	ratAB	operon	including	≈300	bp	
upstream was amplified from E. coli 
MG1655 using primers prCF222/prCF224 
and	ligated	into	pNDM220	after	digestion	
of backbone and insert with BamHI/EcoRI. 
V1	=	strong	SD	and	original	SC	(ATG).	
Expression	of	ratAB	under	endogenous	
transcriptional control
ppasT pCF006_pasT_v1 Derivative	of	ppasTI	(pCF006_pasTI_
v1)	encoding	only	pasT.	Amp	30	µg/
ml
This study; pasI ORF was deleted from 
ppasTI by site-directed mutagenesis using 
primers prCF236/prCF237
pratA pCF006_ratA_v1 Derivative	of	pratAB	(pCF006_ratAB_
v1)	encoding	only	ratA.	Amp	30	µg/
ml
This study; ratB ORF was deleted from 
pratAB	by	site-directed	mutagenesis	using	
primers prCF236/prCF240
pratB pCF006_ratB_v1 Derivative	of	pratAB	(pCF006_ratAB_
v1)	encoding	only	ratB.	Amp	30	µg/
ml
This	study;	ratA	ORF	was	deleted	from	
pratAB	by	site-directed	mutagenesis	using	
primers	prCF238/prCF239
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Identifier Plasmid Genotype/selection Source/description/construction
pCC1736 pCF007_cc1736_v1 Derivative	of	pNDM220	encoding	
cc1736.	Amp	30	µg/ml
This study; codon-optimized cc1736 ORF 
was synthesized by GenScript, amplified 
using primers prCF256/prCF257, and 
ligated	into	pNDM220	downstream	of	
Plac after digestion of backbone and insert 
with BamHI/XhoI digestion. V1 = strong 
RBS and original start codon (CTG). IPTG 
induction of cc1736 expression
pCOQ10 pCF007_coq10_v4 Derivative	of	pNDM220	encoding	
coq10A.	Amp	30	µg/ml
This study; codon-optimized coq10 ORF 
(isoform	A)	was	synthesized	by	GenScript,	
amplified using primers prCF259/prCF290, 
and	ligated	into	pNDM220	downstream	
Plac after digestion of backbone and 
insert	with	BamHI/XhoI.	V4	=	N-terminus	
truncated variant. IPTG induction of 
coq10A	expression
ppasI pCF003_pasI_v1 Derivative	of	pBAD33	encoding	pasI.	
Cam 25 µg/ml
This study; pasI ORF was amplified from 
E. coli CFT073 with a strong RBS and a 
GTG	SC	(AGGAGAaacaattttGTG)	using	
primers prCF166/prCF251 and ligated 
into	pBAD33	downstream	ParaB	after	
digestion of backbone and insert with 
HindIII/XbaI.	Arabinose	induction	of	pasI	
expression. V1 = original SC (GTG) and 
strong RBS
phipA pBAD33	ParaB::	SD4	atg	hipA Derivative	of	pBAD33	encoding	hipA.	
Cam 25 µg/ml
Gerdes	laboratory	collection.	hipA	ORF	
was amplified from E. coli K-12 MG1655 
with	a	strong	RBS	and	an	ATG	SC	
(AAGGAaaaaATG)	using	primers	OEG89/
OEG60 (Germain et al., 2013) and ligated 
into	pBAD33	downstream	ParaB	promoter	
after digestion of backbone and insert with 
XbaI/SphI.	Arabinose	induction	of	hipA	
expression
Abbreviations:	Amp,	Ampicillin;	araC, encodes the regulator of ParaB; bla, β-lactamase-encoding cassette; Cam, Chloramphenicol; cat, 
Chloramphenicol acetyltransferase; IPTG, Isopropyl β-d-1-thiogalactopyranoside; Kan, Kanamycin; lacIq, encodes the repressor of Plac (allele with 
strong lacI expression); ori, plasmid origin of replication; ParaB, promoter inducible with L-arabinose; Plac, Promoter inducible with IPTG; RBS, 
Ribosome binding site; SC, Start codon; TS, temperature-sensitive; λred, recombineering system.
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Organism Strain
GenBank/RefSeq accession 
number
Escherichia coli str. K-12; substr. MG1655 U00096.3/NC_000913.3
Escherichia coli str. CFT073 AE014075.1/NC_004431.1
Escherichia coli str. B; substr. REL606/
Bc251
CP000819.1/NC_012967.1
Escherichia coli str.	UTI89 CP000243.1/NC_007946.1
Shigella flexneri serotype 5a str. M90T CM001474.1/NZ_CM001474.1
Salmonella enterica subsp. enterica; serovar 
Typhimurium;	str.	CT18
AL513382.1/NC_003198.1
Pseudomonas aeruginosa str.	PAO1 AE004091.2/NC_002516.2
Burkholderia cenocepacia str. J2315 Chromosome 1: AM747720.1/
NC_011000.1
Chromosome 2: AM747721.1/
NC_011001.1
Neisseria meningitidis serogroup	B;	str.	MC58 AE002098.2/NC_003112.2
Caulobacter crescentus str.	CB15/ATCC	19089 AE005673.1/NC_002696.2
Myxococcus xanthus str. DK 1622 CP000113.1/NC_008095.1
TA B L E  A 4   Genomes used for the 
synteny analysis of Figure 3
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F I G U R E  A 1  No	growth	inhibition	is	observed	upon	expression	of	pasT (and pasI) under different conditions. (a) Spot assay of E. coli 
CFT073 ΔpasTI mutant harboring isogenic plasmids with different copy number encoding either pasT	or	the	well-studied	TA	module	toxin	
doc (as positive control) under control of a Plac promoter induced on LB agar plates containing 1 mM isopropyl β-d-1-thiogalactopyranoside 
(IPTG) and repressed on LB agar plates containing 1% w/v d-glucose (see Materials and Methods). The expression of pasT did not cause 
growth inhibition under any condition. (b) The same experiment as shown in (a) for E. coli CFT073 ΔpasTI was performed with E. coli K-12 
MG1655 wild-type (top)/ΔratAB	(bottom).	No	growth	inhibition	was	detected	for	pasT expression under any condition. (c) Spot assay of E. coli 
K-12 MG1655 ΔratAB harboring a plasmid encoding either pasI	or	the	well-studied	TA	module	toxin	hipA (as positive control) under control 
of a ParaB promoter induced on agar plates containing 0.2% w/v L-arabinose and repressed on agar plates containing 1% w/v d-glucose (see 
Materials	and	Methods).	No	growth	inhibition	was	detected	for	pasI expression
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F I G U R E  A 2   Biphasic time–kill curves reveal differences in persister levels between E. coli CFT073 and the ΔpasTI mutant. (a) The 
figure shows the time–kill curves of E. coli CFT073 (left) and E. coli K-12 MG1655 (right) strains treated with 10 μg/ml ciprofloxacin 5 hr 
after inoculation into fresh medium (see Materials and Methods). (b) The same experiment as presented in Figure 2a,b for the dynamics of 
ciprofloxacin-tolerant cells was repeated for treatment with 6.6 μg/ml colistin, revealing lower survival of E. coli CFT073 ΔpasTI (but not/
K12 MG1655 ΔratAB)	during	exponential	growth	when	compared	to	the	parental	wild-type.	Note	that	all	strains	seem	to	exhibit	some	
resistance to colistin when the cultures reach high densities (i.e., later than the time points where differences between CFT073 wild-type 
and ΔpasTI become apparent). We suggest that this phenomenon might be caused by the heterogeneous absorption of colistin in a way 
that a subpopulation of nongrowing cells sequesters enough drug to enable residual growth of other cells during the treatment period (as 
shown	before	for	antimicrobial	peptide	LL37	by	Snoussi	et	al.	(2018)).	(c)	The	same	experiment	as	presented	in	Figure	2a,b	for	the	dynamics	
of ciprofloxacin-tolerant cells was repeated for treatment with 100 μg/ml ampicillin (as previously reported for ΔpasTI and ΔratAB mutants 
by	Norton	and	Mulvey	(2012)).	(d)	The	figure	shows	time–kill	curves	of	E. coli CFT073 strains treated with 6.6 μg/ml colistin after 2 hr of 
growth, that is, before any of the cultures have reached high densities. (e) The figure shows time–kill curves of E. coli CFT073 strains treated 
with 100 μg/ml ampicillin after 2 hr of growth, that is, at the minimal survival observed for both wild-type and ΔpasTI mutant (see (c)). The 
regrowth observed after 3 hr in similar ways for both strains is likely due to the high intrinsic resistance of E. coli CFT073 to β-lactams. (f) The 
complementation of decreased colistin survival of E. coli CFT073 ΔpasTI was confirmed by comparing the mutant strain carrying an empty 
vector with an isogenic strain harboring a plasmid encoding pasT	for	complementation.	All	data	points	in	(a-f)	represent	the	mean	of	results	
from	at	least	three	independent	experiments,	and	error	bars	indicate	standard	deviations.	ev	=	empty	vector	(pNDM220)
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F I G U R E  A 3   Differences in persister levels are observed between wild-type and ΔpasTI variants of other E. coli/Salmonella strains. (a) 
The same experiment as presented in Figure 2a-d for the dynamics of E. coli CFT073 ciprofloxacin-tolerant cells was repeated for E. coli 
O157:H7 EDL933 (top left), E. coli	55989	(top	right),	and	Salmonella enterica SR-11 (bottom). (b, c) Time–kill curves for E. coli EDL933 and 
S. enterica SR-11 strains treated with 10 μg/ml ciprofloxacin 5 hr after inoculation into fresh medium reveal that the antibiotic tolerance 
defect of pasTI mutants can be complemented by ectopic expression of CFT073 pasT. We note that there are quantitative differences in the 
results of seemingly similar experiments in (a) and (b) like, for example, the extent of ciprofloxacin sensitivity of the S. enterica SR-11 ΔpasTI 
mutant. These do not qualitatively affect the phenotypes or overall conclusions and are caused by the presence of plasmids (empty vector 
or	complementation	plasmid)	in	(b),	while	strains	in	(a)	harbor	no	plasmid	(see	also	Figure	A6c,d	for	another	phenotype	affected	by	plasmid	
carriage). (d) The pasTI knockout did not affect the ciprofloxacin MIC of any strain except E. coli	55989	where	it	greatly	reduced	intrinsic	
ciprofloxacin resistance. It is therefore possible that for this strain (but not the others) at least part of the different survival between wild-
type and pasTI	knockout	can	be	explained	by	a	difference	in	MIC.	All	data	points	in	(a-d)	represent	the	mean	of	results	from	at	least	three	
independent experiments, and error bars indicate standard deviations. ev = empty vector
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F I G U R E  A 4   In	silico	analysis	of	relationships	between	PasT/RatA	and	Coq10	homologs.	(a)	The	illustration	shows	a	protein	sequence	
alignment of different PasT homologs (generated as described in Materials and Methods). For complementation experiments (e.g., in 
Figure	8),	we	cloned	the	C-terminus	of	Coq10A	that	is	homologous	to	CC1736/PasT	(highlighted	by	a	red	frame;	the	first	and	the	last	amino	
acids	are	indicated)	without	the	N-terminal	mitochondrial	targeting	sequence.	For	completeness,	a	detailed	amino	acid	sequence	alignment	
of PasTCFT073 and Coq10S.cerevisiae is provided. (b) PasT structure prediction using Phyre2 (https://www.sbg.bio.ic.ac.uk/phyre2; Kelley 
et al., 2015). The structure of E. coli CFT073 PasT was modeled with Phyre2 using the best-matching template PDB entry 1t17 (CC1736 of 
Caulobacter crescentus—see	also	Figure	3	and	(a)—and	assigned	a	100%	confidence.	The	N-terminus	and	C-terminus	are	indicated	by	white	
letters. (c) Interaction partners of E. coli	K-12	MG1655	RatA	(left)	and	E. coli	CFT073	PasT	(right)	were	analyzed	using	STRING	(https://strin	
g-db.org/;	Szklarczyk	et	al.,	2018).
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F I G U R E  A 5  Additional	data	related	to	gentamicin	and	zeocin	MIC	experiments.	(a)	Two	additional	independent	replicates	of	the	
gentamicin MIC determination for E. coli CFT073 strains are shown that confirm the phenotype indicated in Figure 4c, Figure 4d, and 
Figure	8b.	(b,	c)	The	experiments	shown	in	Figure	4c,	Figure	4d,	Figure	8b,	and	(a)	were	also	performed	with	E. coli K-12 MG1655 strains 
instead of E. coli CFT073 strains, revealing the same phenotypes of increased gentamicin/zeocin MIC in the absence of functional ratA 
without functional complementation by a homolog. For zeocin, data points represent the mean of results from three independent 
experiments, and error bars indicate standard deviations. (d, e) The MICs of E. coli O157:H7 EDL933, E. coli	55989,	and	S. enterica SR-11 and 
their ΔpasTI derivatives for gentamicin (d) and zeocin (e) were determined by broth dilution assays. The bacteria carried either an empty 
vector (ev) or the complementation plasmid encoding pasT. We did not use the EDL933 strain in (e) because of problems with gentamicin 
resistance. Data points in (d) and (e) represent the mean of results from at least three independent experiments, and error bars indicate 
standard deviation.
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F I G U R E  A 6  Additional	data	related	to	experiments	assessing	oxidative	stress	sensitivity.	(a)	E. coli O157:H7 EDL933, E. coli	55989,	
S. enterica SR-11, and their ΔpasTI derivatives carrying either the empty vector (ev) or the complementation plasmid (ppasT) were spotted 
on LB agar plates to visualize differences in colony size. (b) Cultures of E. coli O157:H7 EDL933, E. coli	55989,	S. enterica SR-11, and their 
ΔpasTI derivatives were diluted and spotted on LB agar plates which we thereafter incubated in the absence of oxygen. d-glucose (1% 
w/v) was added as a fermentable carbon source to LB agar plates incubated anaerobically. (c) Bacterial growth (colony-forming units (cfu)/
ml) and dynamics of cells surviving hydrogen peroxide (H2O2) treatment were determined for cultures of E. coli CFT073 wild-type/ΔpasTI 
(left) and E. coli K-12 MG1655 wild-type/ΔratAB (right) over time after inoculation from stationary phase into fresh medium (see Materials 
and	Methods).	In	contrast	to	Figure	7a,	the	bacteria	do	not	carry	the	empty	vector	pNDM220	of	the	complementation	constructs	used	in	
Figure 7c, but this does not make a difference for E. coli CFT073 (compare the left panels to Figure 7a). (d) The same experiment as described 
in Figure 7a and (a) was performed with E. coli K-12 MG1655 wild-type/ΔratAB	carrying	the	pNDM220	plasmid.	Note	the	difference	in	
H2O2 sensitivity of the ΔratAB mutant in panels (a) and (b) that precluded conclusive complementation experiments for this phenotype with 
E. coli K-12 MG1655 strains. (e) The fraction of cells surviving hydrogen peroxide (H2O2) treatment 2 hr after inoculation was determined 
for cultures of E. coli K-12 MG1655 ΔratAB	with	and	without	pretreatment	with	the	antioxidant	vitamin	C	(ascorbate).	All	data	points	in	(c-e)	
represent the mean of results from at least three independent experiments, and error bars indicate standard deviations. (f) The colony sizes 
of E. coli K-12 MG1655 strains harboring complementation plasmids encoding the pasT homolog cc1736 from C. crescentus or human coq10 
under Plac control were analyzed on LB agar plates supplemented with 1% d-glucose (repressing expression of complementation constructs) 
or 1 mM IPTG (inducing expression of complementation plasmids).
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F I G U R E  A 7   The presence of rpoSam or rpoSwt alleles in E. coli CFT073 ΔpasTI does not affect any phenotype except the dynamics of 
H2O2 survival. (a) Bacterial growth (colony-forming units (cfu)/ml) and dynamics of cells surviving hydrogen peroxide (H2O2) treatment were 
determined for cultures of E. coli CFT073 wild-type/ΔpasTI with intact rpoS (middle panel) in comparison with the E. coli CFT073 strains 
with the rpoSam loss-of-function allele (left panel) and the E. coli K-12 MG1655 strains (right panel). The left and right panels are copied from 
Figure	A6b	to	enable	a	direct	comparison.	(b,	c)	The	dynamics	of	ciprofloxacin	tolerance	throughout	the	growth	phases	of	E. coli CFT073 and 
its ΔpasTI mutant were determined for a variant carrying an intact rpoS	allele	just	like	it	had	been	done	originally	with	the	variant	carrying	
inactive rpoSam (B; compare Figure 2a). Time–kill curves of ciprofloxacin treatment 5 hr after inoculation (c) show biphasic killing kinetics, 
revealing that the difference in survival at this time point is due to different levels of persister cells. (d) The membrane potential of E. coli 
CFT073 rpoSwt and its ΔpasTI	mutant	was	assessed	using	the	fluorescent	indicator	dye	DiOC2(3)	just	as	shown	for	the	rpoSam variants 
in	Figure	4b.	All	data	points	represent	the	mean	of	results	from	at	least	three	independent	experiments,	and	error	bars	indicate	standard	
deviations. (e) Dynamics of colistin tolerance throughout the growth phases of E. coli CFT073, and its ΔpasTI mutant were determined for a 
variant carrying an intact rpoSwt allele as done originally for the variant carrying inactive rpoSam	(Figure	A2b).
